Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation, Tislelizumab, and Lenvatinib in Advanced HCC
NCT05057845Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Sep 2021; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05057845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057845.